(1s,4s)-quinuclidine-3-carbonyl chloride hydrochloride | 83598-29-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 英文名称: (1s,4s)-quinuclidine-3-carbonyl chloride hydrochloride
• 英文别名: (1-azabicyclo[2.2.2]octan-3-yl)carbonyl chloride；1-Azabicyclo[2.2.2]octane-3-carbonyl chloride；quinuclidinyl-3-carboxyl chloride；quinuclidine-3-carbonyl chloride；3-quinuclidinecarbonyl chloride
• CAS: 83598-29-2
• 化学式: C₈H₁₂ClNO
• 分子量: 173.642
• InChiKey: ABQFIARFQRFWAY-UHFFFAOYSA-N

物化性质

• 沸点：
  226.6±23.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1s,4s)-quinuclidine-3-carbonyl chloride hydrochloride 在 吡啶 、 四氯化碳 、 三苯基膦 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 2.33h， 生成 (Z)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl chloride
  参考文献：
  名称：

  Design of [R-(Z)]-(+)-α-(Methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitrile (SB 202026), a Functionally Selective Azabicyclic Muscarinic M1 Agonist Incorporating the N-Methoxy Imidoyl Nitrile Group as a Novel Ester Bioisostere

  摘要：

  Loss of cholinergic function is believed to be implicated in the cognitive decline associated with senile dementia of the Alzheimer type (SDAT). The disease is characterized by progressive loss of muscarinic receptors located on nerve terminals while postsynaptic muscarinic M1 receptors appear to remain largely intact. Muscarinic agonists acting directly on postsynaptic receptors offer the prospect of countering the cholinergic deficit in SDAT. This study describes a novel series of azabicyclic muscarinic agonists, which incorporate an oxime ether or modified oxime ether group as an ester bioisostere. Modification of the oxime ether function by the introduction of electron withdrawing groups led to the finding that the (Z)-N-methoxy imidoyl nitrile group serves as a stable methyl ester bioisostere. This culminated in the discovery of the quinuclidinyl N-methoxy imidoyl nitrile R-(+)-(Z)-5g which is a functionally selective muscarinic M1 partial agonist currently in phase III clinical trials for the treatment of SDAT. The selective profile of R-(+)-(Z)-5g can be rationalized in terms of the relative affinity of the compound at muscarinic receptor subtypes, the degree of agonist efficacy, and brain penetrancy.

  DOI：

  10.1021/jm9702903
• 作为产物：
  描述：

  奎宁环-3-羧酸 在 氯化亚砜 作用下， 生成 (1s,4s)-quinuclidine-3-carbonyl chloride hydrochloride
  参考文献：
  名称：

  （+）-3- [2-（苯并[b]噻吩-2-基）-2-氧代乙基] -1-氮杂双环[2.2.2]辛烷作为α7烟碱乙酰胆碱受体的有效激动剂。

  摘要：

  发现了一系列3-取代的1-氮杂双环[2.2.2]辛烷作为α7烟碱型乙酰胆碱（α7）受体激动剂。结果发现，（+）-3- [2-（苯并[b]噻吩-2-基）-2-氧代乙基] -1-氮杂双环[2.2.2]辛烷（+）-15b具有较强的激动作用。 alpha7受体。

  DOI：

  10.1016/j.bmcl.2004.04.091

文献信息

• [EN] COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE<br/>[FR] COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE LA CHOLINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2013043960A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

  本发明涉及作为胆碱激酶抑制剂的化合物。该发明还提供包含所述化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病、疾病或紊乱的方法。该发明还提供制备本发明化合物的方法。
• FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1396488A1

  公开（公告）日：2004-03-10

  The fused heterocyclic compound of the present invention, which is represented by the formula (I): wherein each symbol is as defined in the specification, an optically active form thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a water adduct thereof show poly(ADP-ribose) synthase inhibitory action and are useful as therapeutic drugs for cerebral infarction.

  本发明的融合杂环化合物，其化学式表示为（I）：其中每个符号如规范中定义，其光学活性形式，其药学上可接受的盐，其水合物和水加合物显示聚(ADP-核糖)合酶抑制作用，并可用作治疗脑梗死的药物。
• Pyrrolidine compounds and medicinal utilization thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US06468998B1

  公开（公告）日：2002-10-22

  The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.

  本发明提供了一种式(I)的吡咯烷化合物，其中每个符号如规范中定义，以及其光学活性化合物和药学上可接受的盐。本发明还提供了一种含有式(I)的化合物、其光学活性化合物或药学上可接受的盐以及药学上可接受的添加剂的药物组合物。本发明的化合物具有血清素2受体拮抗作用，同时具有抑制血小板聚集、改善外周循环和促进泪液分泌的作用。因此，本发明的化合物可以是一种有益的药物，对抗血栓栓塞、干眼症等具有一定效果。
• Novel quinuclidine-based ligands for the muscarinic cholinergic receptor
  作者：John Saunders、Mark Cassidy、Stephen B. Freedman、Elizabeth A. Harley、Leslie L. Iversen、Clare Kneen、Angus M. MacLeod、Kevin J. Merchant、Roger J. Snow、Raymond Baker

  DOI：10.1021/jm00166a008

  日期：1990.4

  been discovered that an oxadiazole ring and related heterocycles can function as bioisosteric replacements for the ester moiety found in several known muscarinic ligands. Within this series there exist compounds which span the efficacy range from high-efficacy agonist through partial agonists to antagonists with affinity comparable or superior to that of classical quaternary ammonium ligands. Consistent

  最近对阿尔茨海默氏病患者的临床研究表明，只有对毒蕈碱样皮质受体表现出高功效的药物才能产生令人鼓舞的结果。本文介绍了新型奎宁环胺基毒蕈碱激动剂的设计，合成和生化特性，这些激动剂可以轻松渗透到中枢神经系统中，并且能够在皮质部位发挥高效作用。通过使用能够测量受体亲和力并预测皮质功效的生化测定法，已发现恶二唑环和相关的杂环可以作为在几种已知毒蕈碱配体中发现的酯部分的生物立体替代物。在这一系列化合物中，存在的化合物的功效范围从高效激动剂到部分激动剂，再到具有与传统季铵配体相当或更高亲和力的拮抗剂。与最近的分子生物学研究一致，结构活性趋势是根据激动剂和拮抗剂的独立结合位点来解释的，其中H-键相互作用表征激动剂行为，而亲脂性结合表征拮抗剂行为。因此，氨基恶二唑部分具有针对激动剂分布进行优化的结构特征。根据激动剂和拮抗剂的单独结合位点来解释结构活性趋势，其中H-键相互作用表征激动剂行为，而亲脂性结合表征拮
• Bicyclic n-arylamides
  申请人：Luithle Joachim

  公开号：US20050107460A1

  公开（公告）日：2005-05-19

  The invention relates to novel bicylic N-arylamides, to a method for the production thereof, and to the use of the same for producing pharmaceuticals for the treatment and/or prophylaxis of diseases and for improving perception, power of concentration, learnig capacity and/or memory retention.

  该发明涉及新型双环N-芳酰胺，以及其生产方法和用途，用于生产用于治疗和/或预防疾病以及改善感知、注意力、学习能力和/或记忆保留的药物。